AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02170857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material will be used in conjunction with the ordinary surgical procedure
Study NCT04687111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
Study NCT04687111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan is an Angiotensin Receptor Blocker
Study NCT01005901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Description: Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
Study NCT01005901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation capsules were provided for use via a SDDPI
Study NCT03556969 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: no intervention
Study NCT03929263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback
Description: Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
Study NCT03549598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET/CT
Description: 5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
Study NCT03549598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FDG PET/CT scan
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
Study NCT03549598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13NH3 PET/CT scan
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
Study NCT00533221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatotropin
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Study NCT00533221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
Study NCT02750696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study NCT00068003 — intervention group
Intervention type: DRUG
Intervention: Anti-CD19 CAR PBL
Study NCT02750696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Study NCT00618826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
Study NCT00618826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
Study NCT00618826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
Study NCT01690195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: See arm description
Study NCT03079167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Study NCT03079167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01025102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naropin 0.1% cum sufentanil
Description: 20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
Study NCT06265909 — intervention group
Intervention type: DEVICE
Intervention: AmDTx
Description: AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
Study NCT02811991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol injection
Description: 325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
Study NCT02811991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline injection
Description: 32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
Study NCT02811991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morhpine PCA
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
Study NCT02811991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morhpine PCA
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
Study NCT04642482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic (Rillus)
Description: Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
Study NCT04642482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
Study NCT00825838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chronic consumption of chili pepper extract
Description: 6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
Study NCT00825838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chronic consumption of matching placebo
Description: 0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
Study NCT04039659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative-pressure wound therapy (PICO)
Description: After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
Study NCT01440985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine Gum 2 mg, Lot number GD922A
Study NCT01440985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine gum 4 mg, Lot number GC962A
Study NCT01440985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine Microtab 2 mg, Lot number GB196G
Study NCT00667303 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal Washes
Description: A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
Study NCT00667303 — intervention group
Intervention type: OTHER
Intervention: Fluorescent antibody detection
Description: For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
Study NCT00667303 — intervention group
Intervention type: OTHER
Intervention: Respiratory viral culture
Description: Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
Study NCT01384747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: 60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
Study NCT01384747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
Study NCT04021498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
Study NCT04021498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
Study NCT03887585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening
Description: Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
Study NCT04724785 — intervention group
Intervention type: OTHER
Intervention: only monitoring
Description: monitoring the viraemia only
Study NCT04724785 — intervention group
Intervention type: OTHER
Intervention: monitoring and regimen change if necessary
Description: if those patients agree, the regimen will be changed.
Study NCT04724785 — intervention group
Intervention type: DRUG
Intervention: regimen change
Description: Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as > 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
Study NCT03182881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymphatic Drainage
Description: It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
Study NCT03182881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
Study NCT05007626 — intervention group
Intervention type: OTHER
Intervention: axial length and refractive error
Description: Comparing the correlation between heterophoria and refraction, even after age adjustment.
Study NCT03602703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry and Western Blot analysis
Description: Diagnostic tests
Study NCT00613392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: powdered antioxidant
Description: one vial mixed with water every day orally or through enteral tube
Study NCT00613392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: powdered cornstarch placebo
Description: one vial mix with water and administer orally or via enteral tube
Study NCT00928850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms
Description: Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
Study NCT00928850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms
Description: Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
Study NCT00928850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms
Description: Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
Study NCT00928850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms
Description: Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
Study NCT04837287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Exercise for 10 Seconds
Description: The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
Study NCT04837287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Exercise for 30 Seconds
Description: The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
Study NCT02589847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: suspension of intestinal microbes
Study NCT02589847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care Antibiotics
Description: Standard of Care Antibiotics
Study NCT02834858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
Study NCT02834858 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT03570203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Sodium
Description: Measurement of serum sodium.
Study NCT01602705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
Study NCT01602705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback of Performance
Description: Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
Study NCT01602705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback of Performance + Health Psychology Informed Intervention
Description: Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
Study NCT03709147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
Study NCT03709147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
Study NCT03709147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
Study NCT03709147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
Study NCT03709147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet
Description: 5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
Study NCT03709147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
Study NCT02585713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Given PO
Study NCT02585713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC
Study NCT02585713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00178217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
Study NCT03845244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow reduction first
Description: -10L/min q 1hr
Study NCT03845244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 reduction first
Description: - 0.1 q 1hr
Study NCT03845244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous (flow and FiO2) reduction
Description: -10L/min and -0.1 q 1hr
Study NCT00361803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: topotecan
Study NCT01050322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Vinorelbine
Description: The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study NCT01050322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Capecitabine
Description: The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study NCT01050322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Lapatinib
Description: The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study NCT04687826 — intervention group
Intervention type: OTHER
Intervention: Goal directed fluid therapy
Description: Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.